MARKET

DRIO

DRIO

DarioHealth
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.79
-0.18
-0.67%
Opening 13:57 02/26 EST
OPEN
27.19
PREV CLOSE
26.97
HIGH
27.65
LOW
24.10
VOLUME
137.95K
TURNOVER
--
52 WEEK HIGH
31.85
52 WEEK LOW
3.020
MARKET CAP
217.38M
P/E (TTM)
-2.6502
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
--Analyst Actions: Cantor Fitzgerald Starts DarioHealth at Overweight With $35 Price Target
MT Newswires · 1d ago
BioMedNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) to Present at Cowen 41st Annual Health Care Conference
Feb 23, 2021 (Investor Brand Network via COMTEX) -- DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics ("DTx") market, today announced...
Investor Brand Network · 3d ago
DarioHealth Announces Participation in the Cowen 41st Annual Healthcare Conference
, /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the company plans to participate in the upcoming Cowen 41 Annual Health Care Conference, a virtual event taking place .
PR Newswire - PRF · 3d ago
BioMedNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) CEO Slated to Host Investor Meetings at Global Healthcare Conference
Feb 19, 2021 (Investor Brand Network via COMTEX) -- DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced that CEO...
Investor Brand Network · 02/19 15:07
DarioHealth to Participate in 10th Annual SVB Leerink Global Healthcare Conference
, /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that , Chief Executive Officer, is scheduled to participate and host investor meetings at the 10th Annual SVB Leerink Global Hea...
PR Newswire - PRF · 02/19 13:30
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 16)
Benzinga · 02/17 12:26
DRIO: Upright Acquisition Expands into MSK Population. Target Up.
By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Upright Technologies Valuation Update DarioHealth Corp. (NASDAQ:DRIO) announced its acquisition of Upright Technologies in a January 27th press release, which was followed by an analy...
Zacks Small Cap Research · 02/16 10:20
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10)
Benzinga · 02/10 12:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRIO. Analyze the recent business situations of DarioHealth through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRIO stock price target is 25.38 with a high estimate of 35.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 3.92M
% Owned: 48.25%
Shares Outstanding: 8.11M
TypeInstitutionsShares
Increased
11
403.06K
New
8
421.54K
Decreased
5
269.87K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.17%
Healthcare Equipment & Supplies
-0.30%
Key Executives
Chairman/Independent Director
Yoav Shaked
President/General Manager
Richard Anderson
Chief Executive Officer/Director
Erez Raphael
Chief Financial Officer/Treasurer/Secretary
Zvi Ben-David
Chief Operating Officer
Dror Bacher
Senior Vice President/Director of Sales
Chris Chan
Senior Vice President
Olivier Jarry
Senior Vice President
Barbara Stark
Vice President
Claudia Kraut
Other
Omar Manejwala
Director
Dennis Matheis
Director
Adam Stern
Independent Director
Allen Kamer
Independent Director
Hila Karah
Independent Director
Dennis McGrath
Independent Director
Dennis Mcgrath
Independent Director
Yadin Shemmer
Independent Director
Richard Stone
  • Dividends
  • Splits
  • Insider Activity
No Data
About DRIO
DarioHealth Corp. (DarioHealth) is a Digital Therapeutics (DTx) company. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. The DTx products are centered around its users and include the Dario Blood Glucose Monitoring System and the Dario Smart Diabetes Management Solution, which are provided to its users in the form of a smartphone application that enables the delivery of content and periodical evidence-based reports; the DarioEngage platform, which provides support and two-way real-time connectivity between its users and their caregivers, and Dario Intelligence, which utilizes user data and is an analytics tool that can assist healthcare providers in the treatments and predictability of diseases. The Company’s services are available direct to consumers via online marketplaces including Amazon, Walmart, Best Buy and the Google and Apple app stores.

Webull offers kinds of DarioHealth Corp stock information, including NASDAQ:DRIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRIO stock methods without spending real money on the virtual paper trading platform.